The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson’s disease
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Our understanding of the etiology, pathophysiology, phenotypic diversity, and progression of Parkinson's disease has stagnated. Consequently, patients do not receive the best care, leading to unnecessary disability, and to mounting costs for society. The Personalized Parkinson Project (PPP) proposes an unbiased approach to biomarker development with multiple biomarkers measured longitudinally. Our main aims are: (a) to perform a set of hypothesis-driven analyses on the comprehensive dataset, correlating established and novel biomarkers to the rate of disease progression and to treatment response; and (b) to create a widely accessible dataset for discovery of novel biomarkers and new targets for therapeutic interventions in Parkinson's disease. METHODS/DESIGN: This is a prospective, longitudinal, single-center cohort study. The cohort will comprise 650 persons with Parkinson's disease. The inclusion criteria are purposely broad: age ≥ 18 years; and disease duration ≤5 years. Participants are followed for 2 years, with three annual assessments at the study center. Outcomes include a clinical assessment (including motor and neuro-psychological tests), collection of biospecimens (stool, whole blood, and cerebrospinal fluid), magnetic resonance imaging (both structural and functional), and ECG recordings (both 12-lead and Holter). Additionally, collection of physiological and environmental data in daily life over 2 years will be enabled through the Verily Study Watch. All data are stored with polymorphic encryptions and pseudonyms, to guarantee the participants' privacy on the one hand, and to enable data sharing on the other. The data and biospecimens will become available for scientists to address Parkinson's disease-related research questions. DISCUSSION: The PPP has several distinguishing elements: all assessments are done in a single center; inclusion of "real life" subjects; deep and repeated multi-dimensional phenotyping; and continuous monitoring with a wearable device for 2 years. Also, the PPP is powered by privacy and security by design, allowing for data sharing with scientists worldwide respecting participants' privacy. The data are expected to open the way for important new insights, including identification of biomarkers to predict differences in prognosis and treatment response between patients. Our long-term aim is to improve existing treatments, develop new therapeutic approaches, and offer Parkinson's disease patients a more personalized disease management approach. TRIAL REGISTRATION: Clinical Trials NCT03364894 . Registered December 6, 2017 (retrospectively registered).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez‐Martin, P., Poewe, W., Sampaio, C., Stern, M. B., Dodel, R., et al. (2008) · Movement Disorders · doi:10.1002/mds.22340 · Cited by 7,536
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Litvan, I., Goldman, J. G., Tröster, A. I., Schmand, B. A., Weintraub, D., Petersen, R. C., Mollenhauer, B., Adler, C. H., Marder, K., Williams‐Gray, C. H., et al. (2012) · Movement Disorders · doi:10.1002/mds.24893 · Cited by 2,609
Multimodal population brain imaging in the UK Biobank prospective epidemiological study
Miller, K. L., Alfaro-Almagro, F., Bangerter, N. K., Thomas, D. L., Yacoub, E., Xu, J., Bartsch, A. J., Jbabdi, S., Sotiropoulos, S. N., Andersson, J. L. R., et al. (2016) · Nature Neuroscience · doi:10.1038/nn.4393 · Cited by 2,020
Validation of the questionnaire for impulsive‐compulsive disorders in Parkinson's disease
Weintraub, D., Hoops, S., Shea, J. A., Lyons, K. E., Pahwa, R., Driver‐Dunckley, E. D., Adler, C. H., Potenza, M. N., Miyasaki, J., Siderowf, A. D., et al. (2009) · Movement Disorders · doi:10.1002/mds.22571 · Cited by 528
Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor
Helmich, R. C., Janssen, M. J. R., Oyen, W. J. G., Bloem, B. R., & Toni, I. (2011) · Annals of Neurology · doi:10.1002/ana.22361 · Cited by 417
Self-citationFeasibility of large-scale deployment of multiple wearable sensors in Parkinson's disease
Silva de Lima, A. L., Hahn, T., Evers, L. J. W., de Vries, N. M., Cohen, E., Afek, M., Bataille, L., Daeschler, M., Claes, K., Boroojerdi, B., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0189161 · Cited by 162
Self-citationParkinson’s Disease Subtypes in the Oxford Parkinson Disease Centre (OPDC) Discovery Cohort
Lawton, M., Baig, F., Rolinski, M., Ruffman, C., Nithi, K., May, M. T., Ben-Shlomo, Y., & Hu, M. T. M. (2015) · Journal of Parkinson’s Disease · doi:10.3233/jpd-140523 · Cited by 100
Cited by
Helmich, R. C., & Bloem, B. R. (2020) · Journal of Parkinson's Disease · doi:10.3233/jpd-202038 · Cited by 300
Self-citationvan der Heide, A., Meinders, M. J., Bloem, B. R., & Helmich, R. C. (2020) · Journal of Parkinson’s Disease · doi:10.3233/jpd-202251 · Cited by 126
Self-citationTaylor, K. I., Staunton, H., Lipsmeier, F., Nobbs, D., & Lindemann, M. (2020) · npj Digital Medicine · doi:10.1038/s41746-020-0305-8 · Cited by 85
Accelerating Parkinson’s Disease drug development with federated learning approaches
Khanna, A., Adams, J., Antoniades, C., Bloem, B. R., Carroll, C., Cedarbaum, J., Cosman, J., Dexter, D. T., Dockendorf, M. F., Edgerton, J., et al. (2024) · npj Parkinson's Disease · doi:10.1038/s41531-024-00837-5 · Cited by 21
“Among numerous opportunities, data from the Oxford Parkinson ’ s Disease Cohort 50 , PPMI 51 , MJFF 52 , AMP ® -PD 75 , Mobilise-D 76 , PPP 53 , OXQUIP 65 , the Global Parkinson ’ s Genetics Program 77 , and European Platform for Neurodegenerative Diseases 78 are potential sources.”
Self-citationChallenges and Potential of Using Digital Biomarkers in Healthcare and Clinical Trials
Lieberwirth, J. K., Mittermaier, M., & Stern, A. D. (2026) · Communications Medicine · doi:10.1038/s43856-026-01450-8 · Cited by 13
Metadata
- Authors
- Bloem, B. R., Marks, W. J., Silva de Lima, A. L., Kuijf, M. L., van Laar, T., Jacobs, B. P. F., Verbeek, M. M., Helmich, R. C., van de Warrenburg, B. P., Evers, L. J. W., intHout, J., van de Zande, T., Snyder, T. M., Kapur, R., & Meinders, M. J.
- Venue
- BMC Neurology
- Published
- 2019-07-17
- Volume
- 19
- Issue
- 1
- Pages
- 160-160
- ISSN
- 1471-2377 (ISSN-L)
- OpenAlex
- W2958882697
- Cited by
- 117
- References
- 8
- FWCI
- 8.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson’s disease. https://app.cochat.ai/papers/10.1186/s12883-019-1394-3
- The paper
- Bloem, B. R., Marks, W. J., Silva de Lima, A. L., Kuijf, M. L., van Laar, T., Jacobs, B. P. F., Verbeek, M. M., Helmich, R. C., van de Warrenburg, B. P., Evers, L. J. W., intHout, J., van de Zande, T., Snyder, T. M., Kapur, R., & Meinders, M. J. (2019). The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson’s disease. BMC Neurology. https://doi.org/10.1186/s12883-019-1394-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.